Five year summary 12 months to 12 months to 12 months to 12 months to 12 months to 31 Dec 1999 31 Dec 2000 31 Dec 2001 31 Dec 2002 31 Dec 2003 restated restated restated m m m m m Key data Sales 1,375 1,378 1,603 1,618 1,652 1,271 1,378 1,603 1,618 1,652 continuing operations discontinued operations 104 - - - - Amersham Health 178 195 241 256 228 Amersham Biosciences 82 63 72 75 97 Corporate 10 17 21 21 26 Operating profit of continuing operations before exceptional items and goodwill 299 amortisation 250 241 292 310 Discontinued operations 10 - - - - Total operating profit before exceptional items and goodwill amortisation 260 241 292 310 299 Interest 27 10 9 7 5 Amounts written off investments - - 4 2 - Profit before tax and before exceptional items and goodwill amortisation 233 231 279 301 294 Exceptional items 55 27 47 - 58 Goodwill amortisation 9 11 12 37 44 Profit before taxation after exceptional items and goodwill amortisation 169 193 314 264 192 Profit attributable to shareholders 88 107 211 179 116 Employment of shareholders funds Fixed assets 677 777 788 1,491 1,498 Net current assets 360 266 270 147 92 Non-current liabilities incl.
Figures for periods ending 31 December 1999, 2000 and 2001 have been restated following the introduction of FRS 19 in the year ended 31 December 2002.
During the period ending 31 December 2003, the results of Amersham Biosciences have been further segmented into Protein Separations and Discovery Systems.
The current and comparative information can be found in note 1 to the financial statements.
